Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: Effects of chronic treatment with typical and atypical antipsychotic drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 2, 1997, Pages 939-946

  Lidow, Michael S ^a,b   Goldman Rakic, Patricia S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; HALOPERIDOL; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; REMOXIPRIDE; RISPERIDONE; TIAPRIDE; DOPAMINE 1 RECEPTOR; DRD4 PROTEIN, HUMAN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; MACACA; NEOSTRIATUM; NONHUMAN; ORAL DRUG ADMINISTRATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TEMPORAL CORTEX; ANIMAL; CORPUS STRIATUM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; CORPUS STRIATUM; HUMANS; MACACA MULATTA; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RNA, MESSENGER;

EID: 0030612278     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. 4 dopamine receptors. Soc. Neurosci. Abstr. 22: 482, 1996.
2. BANNON, M. J. AND ROTH, R. H.: Pharmacology of mesocortical dopamine neurons. Pharmacol. Rev. 35: 53-68, 1983.
3. 2 dopamine and muscarinic cholinergic receptors in rat striatum. J. Pharmacol. Exp. Ther. 244: 987-993, 1988.
4. BRODMANN, K.: Localisation in the Cerebral Cortex, translated by L. J. Garey. Smith-Gordon, London, 1994.
5. BRUNELLO, N., MASOTTO, C., STEARDO, L., MARKSTEIN, R. AND RACAGNI, G.: New insighnts into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13: 177-213, 1995.
6. BURMA, O. J. S., Roos, R. A. C., BRUYN, G. W., KEMP, B. AND VAN DER VELDE, E. A.: Tiapride in the treatment of tardive dyskinesia. Acta Neurol. Scand. 65: 38-44, 1982.
7. COWARD, D. M.: General pharmacology of clozapine. Br. J. Psychiatr. 160: 5-11, 1992.
8. DANIEL, D. G., GOLDBERG, T. E., WEINBERGER, D. R., KLEINMAN, J. E., PICKARD, D., LUBICK, L. J. AND WILLIAMS, T. S.: Different side effects of resperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: A pilot study. Am. J. Psychiatry 153: 417-419, 1996.
9. EGGERS, C., ROTHENBERGER, A. AND BERGHANS, U.: Clinical and neurobiological findings in children suffering from disease following treatment with tiapride. Eur. Arch. Psychiatr. Neurol. Sci. 237: 223-229, 1988.
10. FARDE, L. AND NORDSTROM, A.-L.: PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br. J. Psychiatr. 160: 30-33, 1992.
11. 2 receptor occupancy in clozapine-treated patients. J. Clin. Psychiatr. 55: 67-69, 1994.
12. FITTON, A. AND BENFIELD, P.: Clozapine: An appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. Pharmacoeconomics 4: 131-156, 1993.
13. 2 dopamine receptor isoforms. Nature 342: 923-926, 1989.
14. GOLDMAN-RAKIC, P. S.: Prefrontal cortical dysfunction in schizophrenia: The relevance of working memory. In Psychopathology and the Brain, ed. by B. J. Carroll and E. J. Barrett, pp. 1-23, Raven Press, New York, 1991.
15. GOLDMAN-RAKIC, P. S., SELEMON, L. D.: Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. In press.
16. HYMAN, S. E. AND ARANA, G. W.: Handbook of Psychiatric Drug Therapy. Little, Brown & Co., Boston, 1987.
17. 2 receptors: Distribution, pharmacological characterization and region-specific regulation by clozapine. J. Pharmacol. Exp. Ther. 261: 1282-1290, 1992.
18. 2 antagonistic properties. J. Pharmacol. Exp. Ther. 344: 685-693, 1988.
19. JONES, E. G.: Anatomy of cerebral cortex: Collumnar input-output organization. In The Organization of Cerebral Cortex, ed. by F. O. Schmitt, F. G. Worden, S. G. Dennis and G. Adelman, pp. 199-235, MIT Press, Cambridge, 1981.
20. KAROUM, F. AND EGAN, M. F.: Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens and striatum: A comparison of acute clozapine and haloperidol. Br. J. Pharmacol. 105: 703-707, 1992.
21. 4 receptors in rat frontal cortex. J. Neural Transm. 101: 231-235, 1995.
22. 3H]-NGD-94-1. Soc. Neurosci. Abstr. 22: 1580, 1996.
23. 2) receptor numbers in the rat brain. Psychiatr. Res. 12: 277-285, 1984.
24. 2-dopamine receptors in the primate cerebral cortex. Proc. Natl. Acad. Sci. USA 91: 4353-4356, 1994.
25. 5 dopamine receptors in the primate prefrontal cortex. Synapse. In press.
26. 5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J. Pharmacol. Exp. Ther. 281: 579-603, 1997.
27. LUCHINS, D.: The dopamine hypothesis of schizophrenia: A critical analysis. Neuropsychobiology 1: 365-78, 1975.
28. 3 receptors. Mol. Pharmacol. 43: 749-754, 1993.
29. MATSUBARA, S., MATSUBARA, R., KUSUMI, I., KOYAMA, T. AND YAMASHITA, I.: Dopamine D1, D2 and serotonin-2 receptor occupancy by typical and atypical drugs in vivo. J. Pharmacol. Exp. Ther. 265: 498-508.
30. MCCLAVE, J. T. AND DIETRICH, F. H.: Statistics, pp. 407-481, Dellen Publishing Co., San Francisco, 1985.
31. MEADOR-WOODRUFF, J. H., DAMASK, S. P., WANG, J., HAROUTUNIAN, V., DAVIS, K. L. AND WATSON, S. J.: Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15: 17-29, 1996.
32. MEFFORD, I. N., ROTH, K. A., AGREN, H. AND BARCHAS, J. D.: Enhancement of dopamine metabolism in rat brain frontal cortex: A common effect of chronically administered antipsychotic drugs. Brain Res. 475: 380-384, 1988.
33. MELTZER, H. Y.: Clozapine: Mechanism of action in relation to its clinical advantages. In Recent Advances in Schizophrenia, ed by A. Kales, C. N. Stefanis, and J. A. Talbott, pp. 237-256, Springer-Verlag, New York, 1990.
34. i values. J. Pharmacol. Exp. Ther. 251: 238-246, 1989.
35. MELTZER, H. Y. AND STAHL, S. M.: The dopamine hypothesis of schizophrenia: A review. Schizophr. Bull. 2: 19-76, 1976.
36. 2 dopamine receptors produced by alternative RNA splicing. Nature 342: 926-929, 1989.
37. MOORE, N. A., TUPPER, D. E., HOTTEN, T. M.: The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. Drugs Future. 19: 114-117, 1994.
38. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15: 2186-2191, 1995.
39. 4 receptor gene: Frequent occurrence of a null allele and observations of the homozygosity. Human Mol. Genet. 3: 2207-2212, 1994.
40. 1 receptors in schizophrenia revealed by PET. Nature 385: 634-635, 1997.
41. O'DELL, S., LAHOSTE, G. J., WIDMARK, C. B., SHAPIRO, R. M., ROTKIN, S. G. AND MARSHALL, J. F.: Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6: 146-153, 1990.
42. O'Dowd, B. F., SEEMAN, P. AND GEORGE, S. R.: Dopamine receptor. In Handbook of Receptors and Channels: G Protein-Coupled Receptors, ed. by S. J. Peroutka, pp. 95-123, CRC Press, Ann Arbor, 1994.
43. PFLUG, B., BARTELS, M., BANER, H., BUNSE, J., GALLHOFER, B., HAAS, S., KONZOW, W. T. H., LKIESER, E., KUFFERLE, B., STEIN, D., STEINBERG, K. A. AND WEISELMANN, G.: A double-blind multicentre study comparing remoxipride controlled release formulation with haloperidol in schizophrenia. Acta Psychiatr. Scand. 82: Suppl. 358, 142-146, 1990.
44. PHYSICIANS' DESK REFERENCE, 50th ed. Medical Economics, Oradell, NJ, 1996.
45. 4 receptors increased in schizophrenia? J. Neurochem. 63: 1576-1577, 1994.
46. 4 receptors in drug-treated schizophrenia. Eur. J. Pharmacol. 281: R5-R6, 1995.
47. ROTH, B. L., TANDRA, S., BURGESS, L. H., SIBLEY, D. R. AND MELTZER, H. Y.: D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120: 365-368, 1995.
48. 2 receptor function in the rat. Biochem. Pharmacol. 34: 2755-2763, 1985.
49. SAYED, Y. AND GARRISON, J. M.: The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs: A review. Psychopharmacol. Bull. 19: 283-288, 1983.
50. SCHERER, J., TATSCH, K., SCHWARZ, J., OERTEL, W., KIRSCH, M. C. AND ALBUS, M.: Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol. Psychiatr. 36: 627-629, 1994.
51. SCHWARTZ, M. L. AND GOLDMAN-RAKIC, P. S.: Callosal and intrahemispheric connectivity of the prefrontal association cortex in rhesus monkey: Relation between intraparietal and principal sulcal cortx. J. Comp. Neurol. 226: 403-420, 1998.4.
52. SEEMAN, P.: Dopamine receptor sequences: Therapeutic levels of neuroleptic occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7: 261-284, 1992.
53. SEEMAN, P., GUAN, H.-C. AND VANTOL, H. H.: Dopamine D4 receptors elevated in schizophrenia. Nature 365: 441-445, 1993a.
54. 4 receptors in Parkinson's schizophrenia and control brain striata. Synapse. 14: 247-253, 1993b.
55. SEEMAN, P., ULPIAN, C., CHOUINARD, G., VANTOL, H. H. M., DWOSH, H., LEIBERMAN, J. A., SIMINOVITCH, K., LIU, I. S. C., WAYE, J., VORUGANTI, P., HUDSON, C., SERJEANT, G. R., MASIBAY, A. S. AND SEEMAN, M. V.: Dopamine D4 receptor variant, D4glicine 194 in Africans, but not in Caucasians: No association with schizophrenia. Am. J. Med. Genet. 54: 384-390, 1994.
56. SHENTON, M. E., KIKINS, R. D., JOLESZ, F. A., POLLAK, S. D., LEMAY, M., WIBLE, C. G., HOKAMA, H., MARTIN, J., METCALF, D., COLEMAN, M. AND MCGARLEY, R. W.: Abnormalities of the left temporal lobe and thought disorder in schizophrenis. N. Engl. J. Med. 327: 604-612, 1992.
57. SNYDER, S. H.: The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am. J. Psychiatry 133: 197-202, 1976.
58. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res. 681: 109-116, 1995.
59. VAN KAMMEN, D. P.: The dopamine hypothesis of schizophrenia revisited. Psychoneuroendocrinology 4: 37-46, 1979.
60. VAN PRAAG, H. M. AND KORF. J.: The dopamine hypothesis of schizophrenia: Some direct observations. In On the Origin of Schizophrenic Psychoses, ed by H. M. Van Praag, pp. 81-98, De Erven, Bohn B. V. Amsterdam, 1975.
61. VANTOL, H. H. M., BUNZOW, J. R., GUAN, H. C., SUNAHARA, R. K., SEEMAN, P., NIZNIK, H. AND CIVELLI, O.: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-613, 1991.
62. WALKER, A. E.: A cytoarchitectural study of the prefrontal area of the macaque monkey. J. Comp. Neurol. 73: 59-86, 1940.
63. WEINBERGER, D. R.: Schizophrenia and the frontal lobe. Trends Neurosci. 11: 367-370, 1988.
64. WEINBERGER, D. R.: Anteromedial temporal-prefrontal connectivity: A functional neuroanatomical system implicated in schizophrenia. In Psychopathology and the Brain, ed. by B. J. Carroll and J. E. Barrett, pp. 25-43, Raven Press, New York, 1991.
65. 1 receptors in prefrontal cortex. Nature 376: 572-575, 1995.
66. 2) receptors in the rat brain. Brain Res. 487: 288-298, 1989.